Aclaris Therapeutics (ACRS) Invested Capital (2017 - 2025)
Historic Invested Capital for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $120.1 million.
- Aclaris Therapeutics' Invested Capital fell 772.26% to $120.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $120.1 million, marking a year-over-year decrease of 772.26%. This contributed to the annual value of $155.6 million for FY2024, which is 103.39% down from last year.
- According to the latest figures from Q3 2025, Aclaris Therapeutics' Invested Capital is $120.1 million, which was down 772.26% from $131.7 million recorded in Q2 2025.
- In the past 5 years, Aclaris Therapeutics' Invested Capital registered a high of $244.5 million during Q2 2021, and its lowest value of $120.1 million during Q3 2025.
- Moreover, its 5-year median value for Invested Capital was $157.2 million (2023), whereas its average is $170.7 million.
- As far as peak fluctuations go, Aclaris Therapeutics' Invested Capital surged by 32160.99% in 2021, and later plummeted by 2888.72% in 2023.
- Over the past 5 years, Aclaris Therapeutics' Invested Capital (Quarter) stood at $197.3 million in 2021, then rose by 0.14% to $197.6 million in 2022, then fell by 20.46% to $157.2 million in 2023, then fell by 1.03% to $155.6 million in 2024, then decreased by 22.79% to $120.1 million in 2025.
- Its Invested Capital stands at $120.1 million for Q3 2025, versus $131.7 million for Q2 2025 and $144.1 million for Q1 2025.